Massachusetts General Hospital Mass General 2

Boston, Massachusetts 02115

0 studies enrolling now · 5 studies all time

What they study most

Advanced Solid Tumors, BRAF Mutated Melanoma, Breast Cancer, Metastatic Pancreatic Adenocarcinoma, Selected Solid Tumors, Solid Tumor, Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein, Unspecified Adult Solid Tumor, Protocol Specific

Studies at this site

• A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors — Stopped early
• PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer — Completed
• Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients — Completed
• Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients — Completed
• A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer — Completed